|
|
Vaccine Detail
|
Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine |
| Vaccine Information |
- Vaccine Name: Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007062
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- L1
gene engineering:
- Description: This is for Cervical Cancer (NCT00411749). A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts (Garland et al., 2022; NCIT_C61087).
|
| Host Response |
|
|
| References |
Garland et al., 2022: Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. Human vaccines & immunotherapeutics. 2022; 18(6); 2105067. [PubMed: 35997582].
NCIT_C61087: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61087]
NCT00411749: [https://clinicaltrials.gov/ct2/show/NCT00411749?term=V501&rank=1]
|
|
